vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and INNOSPEC INC. (IOSP). Click either name above to swap in a different company.
INNOSPEC INC. is the larger business by last-quarter revenue ($453.2M vs $281.3M, roughly 1.6× Guardant Health, Inc.). INNOSPEC INC. runs the higher net margin — 6.8% vs -45.7%, a 52.5% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 2.8%). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 2.1%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Innospec Inc., formerly known as Octel Corporation and Associated Octel Company, Ltd., is an American specialty chemical company. It comprises three business units:The Performance Chemicals business trades in the personal care, home care, agrochemical, mining and industrial markets. The Fuel Specialties business specializes in manufacturing and supplying fuel additives. The Oilfield Services business supplies drilling, completion and production chemicals.
GH vs IOSP — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $453.2M |
| Net Profit | $-128.5M | $30.8M |
| Gross Margin | 64.6% | 27.3% |
| Operating Margin | -43.0% | 8.1% |
| Net Margin | -45.7% | 6.8% |
| Revenue YoY | 39.4% | 2.8% |
| Net Profit YoY | -15.8% | -8.3% |
| EPS (diluted) | $-1.01 | $1.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $453.2M | ||
| Q4 25 | $281.3M | $455.6M | ||
| Q3 25 | $265.2M | $441.9M | ||
| Q2 25 | $232.1M | $439.7M | ||
| Q1 25 | $203.5M | $440.8M | ||
| Q4 24 | $201.8M | $466.8M | ||
| Q3 24 | $191.5M | $443.4M | ||
| Q2 24 | $177.2M | $435.0M |
| Q1 26 | — | $30.8M | ||
| Q4 25 | $-128.5M | $47.4M | ||
| Q3 25 | $-92.7M | $12.9M | ||
| Q2 25 | $-99.9M | $23.5M | ||
| Q1 25 | $-95.2M | $32.8M | ||
| Q4 24 | $-111.0M | $-70.4M | ||
| Q3 24 | $-107.8M | $33.4M | ||
| Q2 24 | $-102.6M | $31.2M |
| Q1 26 | — | 27.3% | ||
| Q4 25 | 64.6% | 28.0% | ||
| Q3 25 | 64.7% | 26.4% | ||
| Q2 25 | 65.0% | 28.0% | ||
| Q1 25 | 63.3% | 28.4% | ||
| Q4 24 | 61.6% | 29.2% | ||
| Q3 24 | 61.1% | 28.0% | ||
| Q2 24 | 59.1% | 29.2% |
| Q1 26 | — | 8.1% | ||
| Q4 25 | -43.0% | 10.3% | ||
| Q3 25 | -37.3% | 1.3% | ||
| Q2 25 | -45.9% | 7.8% | ||
| Q1 25 | -54.6% | 9.6% | ||
| Q4 24 | -62.4% | 8.8% | ||
| Q3 24 | -61.3% | 10.3% | ||
| Q2 24 | -56.8% | 9.4% |
| Q1 26 | — | 6.8% | ||
| Q4 25 | -45.7% | 10.4% | ||
| Q3 25 | -35.0% | 2.9% | ||
| Q2 25 | -43.0% | 5.3% | ||
| Q1 25 | -46.8% | 7.4% | ||
| Q4 24 | -55.0% | -15.1% | ||
| Q3 24 | -56.3% | 7.5% | ||
| Q2 24 | -57.9% | 7.2% |
| Q1 26 | — | $1.22 | ||
| Q4 25 | $-1.01 | $1.90 | ||
| Q3 25 | $-0.74 | $0.52 | ||
| Q2 25 | $-0.80 | $0.94 | ||
| Q1 25 | $-0.77 | $1.31 | ||
| Q4 24 | $-0.90 | $-2.80 | ||
| Q3 24 | $-0.88 | $1.33 | ||
| Q2 24 | $-0.84 | $1.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $289.1M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.4B |
| Total Assets | $2.0B | $1.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $289.1M | ||
| Q4 25 | $378.2M | $292.5M | ||
| Q3 25 | $580.0M | $270.8M | ||
| Q2 25 | $629.1M | $266.6M | ||
| Q1 25 | $698.6M | $299.8M | ||
| Q4 24 | $525.5M | $289.2M | ||
| Q3 24 | $585.0M | $303.8M | ||
| Q2 24 | $933.7M | $240.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $-99.3M | $1.3B | ||
| Q3 25 | $-354.5M | $1.3B | ||
| Q2 25 | $-305.5M | $1.3B | ||
| Q1 25 | $-250.8M | $1.3B | ||
| Q4 24 | $-139.6M | $1.2B | ||
| Q3 24 | $-60.1M | $1.2B | ||
| Q2 24 | $-1.6M | $1.2B |
| Q1 26 | — | $1.8B | ||
| Q4 25 | $2.0B | $1.8B | ||
| Q3 25 | $1.3B | $1.8B | ||
| Q2 25 | $1.3B | $1.8B | ||
| Q1 25 | $1.3B | $1.8B | ||
| Q4 24 | $1.5B | $1.7B | ||
| Q3 24 | $1.5B | $1.8B | ||
| Q2 24 | $1.6B | $1.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $17.6M |
| Free Cash FlowOCF − Capex | $-54.2M | — |
| FCF MarginFCF / Revenue | -19.3% | — |
| Capex IntensityCapex / Revenue | 9.9% | 2.0% |
| Cash ConversionOCF / Net Profit | — | 0.57× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $17.6M | ||
| Q4 25 | $-26.4M | $61.4M | ||
| Q3 25 | $-35.4M | $39.3M | ||
| Q2 25 | $-60.3M | $9.3M | ||
| Q1 25 | $-62.7M | $28.3M | ||
| Q4 24 | $-64.5M | $25.7M | ||
| Q3 24 | $-51.1M | $73.5M | ||
| Q2 24 | $-94.0M | $4.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-54.2M | $46.8M | ||
| Q3 25 | $-45.8M | $25.0M | ||
| Q2 25 | $-65.9M | $-3.7M | ||
| Q1 25 | $-67.1M | $19.9M | ||
| Q4 24 | $-83.4M | $13.6M | ||
| Q3 24 | $-55.3M | $65.8M | ||
| Q2 24 | $-99.1M | $-6.2M |
| Q1 26 | — | — | ||
| Q4 25 | -19.3% | 10.3% | ||
| Q3 25 | -17.3% | 5.7% | ||
| Q2 25 | -28.4% | -0.8% | ||
| Q1 25 | -33.0% | 4.5% | ||
| Q4 24 | -41.3% | 2.9% | ||
| Q3 24 | -28.9% | 14.8% | ||
| Q2 24 | -55.9% | -1.4% |
| Q1 26 | — | 2.0% | ||
| Q4 25 | 9.9% | 3.2% | ||
| Q3 25 | 3.9% | 3.2% | ||
| Q2 25 | 2.4% | 3.0% | ||
| Q1 25 | 2.2% | 1.9% | ||
| Q4 24 | 9.4% | 2.6% | ||
| Q3 24 | 2.2% | 1.7% | ||
| Q2 24 | 2.9% | 2.5% |
| Q1 26 | — | 0.57× | ||
| Q4 25 | — | 1.30× | ||
| Q3 25 | — | 3.05× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.20× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
IOSP
Segment breakdown not available.
